|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's range||107.61 - 109.63|
|52-week range||66.90 - 116.81|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||107.36|
|Forward dividend & yield||0.80 (0.74%)|
|Ex-dividend date||11 Dec 2019|
|1y target est||N/A|
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.